| The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ... The lancet Respiratory medicine 5 (4), 291-360, 2017 | 707 | 2017 |
| Serum drug concentrations predictive of pulmonary tuberculosis outcomes JG Pasipanodya, H McIlleron, A Burger, PA Wash, P Smith, T Gumbo The Journal of infectious diseases 208 (9), 1464-1473, 2013 | 501 | 2013 |
| Pulmonary impairment after tuberculosis JG Pasipanodya, TL Miller, M Vecino, G Munguia, R Garmon, S Bae, ... Chest 131 (6), 1817-1824, 2007 | 337 | 2007 |
| Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability S Srivastava, JG Pasipanodya, C Meek, R Leff, T Gumbo The Journal of infectious diseases 204 (12), 1951-1959, 2011 | 336 | 2011 |
| Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy JG Pasipanodya, S Srivastava, T Gumbo Clinical Infectious Diseases 55 (2), 169-177, 2012 | 290 | 2012 |
| Post-tuberculosis lung health: perspectives from the First International Symposium BW Allwood, MM Van Der Zalm, AFS Amaral, A Byrne, S Datta, U Egere, ... The International Journal of Tuberculosis and Lung Disease 24 (8), 820-828, 2020 | 173 | 2020 |
| A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients JG Pasipanodya, T Gumbo Clinical Infectious Diseases 57 (1), 21-31, 2013 | 160 | 2013 |
| Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis E Chigutsa, JG Pasipanodya, ME Visser, PD Van Helden, PJ Smith, ... Antimicrobial agents and chemotherapy 59 (1), 38-45, 2015 | 148 | 2015 |
| Pulmonary impairment after tuberculosis and its contribution to TB burden JG Pasipanodya, SJN McNabb, P Hilsenrath, S Bae, K Lykens, E Vecino, ... BMC public health 10, 1-10, 2010 | 141 | 2010 |
| Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis K Dheda, L Lenders, G Magombedze, S Srivastava, P Raj, E Arning, ... American journal of respiratory and critical care medicine 198 (9), 1208-1219, 2018 | 140 | 2018 |
| Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis JG Pasipanodya, TL Miller, M Vecino, G Munguia, S Bae, G Drewyer, ... Chest 132 (5), 1591-1598, 2007 | 135 | 2007 |
| An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future J Pasipanodya, T Gumbo Antimicrobial agents and chemotherapy 55 (1), 24-34, 2011 | 126 | 2011 |
| Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests S Swaminathan, JG Pasipanodya, G Ramachandran, AK Hemanth Kumar, ... Clinical Infectious Diseases 63 (suppl_3), S63-S74, 2016 | 121 | 2016 |
| Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence JG Pasipanodya, D Ogbonna, BE Ferro, G Magombedze, S Srivastava, ... Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01206-17, 2017 | 118 | 2017 |
| The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, M Murray, J Furin, ... The Lancet Respiratory Medicine 7 (9), 820-826, 2019 | 110 | 2019 |
| Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis S Srivastava, G Magombedze, T Koeuth, C Sherman, JG Pasipanodya, ... Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00751-17, 2017 | 105 | 2017 |
| A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs JG Pasipanodya, T Gumbo Current opinion in pharmacology 11 (5), 457-463, 2011 | 101 | 2011 |
| Personal and societal health quality lost to tuberculosis TL Miller, SJN McNabb, P Hilsenrath, J Pasipanodya, SE Weis PloS one 4 (4), e5080, 2009 | 98 | 2009 |
| Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis D Deshpande, JG Pasipanodya, SG Mpagama, P Bendet, S Srivastava, ... Clinical Infectious Diseases 67 (suppl_3), S293-S302, 2018 | 93 | 2018 |
| Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used JG Pasipanodya, T Gumbo Antimicrobial agents and chemotherapy 54 (7), 2847-2854, 2010 | 93 | 2010 |
Shashikant SrivastavaAssociate Professor Department of Medicine, UT Tyler School of Medicine在 uthct.edu 的电子邮件经过验证
